Andreas D Meid1, Anna von Medem1,2, Dirk Heider3, Jürgen-Bernhard Adler4, Christian Günster4, Hanna M Seidling1,2, Renate Quinzler1, Hans-Helmut König3, Walter E Haefeli5. 1. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 2. Cooperation Unit Clinical Pharmacy, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 3. Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Germany. 5. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. walter.emil.haefeli@med.uni-heidelberg.de.
Abstract
INTRODUCTION: Drugs that potentially prolong the QT interval carry the risk of life-threatening Torsades de pointes (TdP) ventricular arrhythmia. OBJECTIVE: The objective of this study was to investigate the potential additive risk for ventricular arrhythmia with concomitant prescriptions of QT-prolonging drugs. METHODS: Claims data for persons aged ≥65 years between 2010 and 2012 in Germany were analyzed and all cases hospitalized for ventricular arrhythmia were selected. In a case-crossover analysis, exposure with QT-prolonging drugs according to the Arizona Center for Education and Research on Therapeutics (AZCERT) classification of 'known,' 'conditional,' and 'possible' TdP risk was determined in respective event and control windows preceding hospitalization. Conditional logistic regression was applied to derive odds ratios (ORs). RESULTS: Among 6,849,622 health-insured persons, we identified 2572 patients newly hospitalized for ventricular arrhythmia. Drugs with 'known' risk were more frequently prescribed in the event window than in the control window (309 vs. 239; P < 0.001). The number of drugs with an attributed 'known' risk of TdP was significantly associated with hospitalization for ventricular arrhythmia (OR: 2.22; 95% confidence interval [1.51-3.25]; P < 0.001), while increased risk estimates were also obtained upon categorization into one and two or more drugs compared with no drugs for the combined group of drug with 'known' (1.52 [1.16-2.00]) and 'conditional' risk (2.20 [1.42-3.41]). Pairwise comparisons and trend tests based on these classification categories could not demonstrate a significantly increased risk of two or more drugs compared with one drug. CONCLUSION: Beyond suitable single-drug classifications for QT-associated risk estimation, the situation when there is co-prescription of several drugs appears to be complex and may not be extrapolated to all possible multi-drug combinations.
INTRODUCTION: Drugs that potentially prolong the QT interval carry the risk of life-threatening Torsades de pointes (TdP) ventricular arrhythmia. OBJECTIVE: The objective of this study was to investigate the potential additive risk for ventricular arrhythmia with concomitant prescriptions of QT-prolonging drugs. METHODS: Claims data for persons aged ≥65 years between 2010 and 2012 in Germany were analyzed and all cases hospitalized for ventricular arrhythmia were selected. In a case-crossover analysis, exposure with QT-prolonging drugs according to the Arizona Center for Education and Research on Therapeutics (AZCERT) classification of 'known,' 'conditional,' and 'possible' TdP risk was determined in respective event and control windows preceding hospitalization. Conditional logistic regression was applied to derive odds ratios (ORs). RESULTS: Among 6,849,622 health-insured persons, we identified 2572 patients newly hospitalized for ventricular arrhythmia. Drugs with 'known' risk were more frequently prescribed in the event window than in the control window (309 vs. 239; P < 0.001). The number of drugs with an attributed 'known' risk of TdP was significantly associated with hospitalization for ventricular arrhythmia (OR: 2.22; 95% confidence interval [1.51-3.25]; P < 0.001), while increased risk estimates were also obtained upon categorization into one and two or more drugs compared with no drugs for the combined group of drug with 'known' (1.52 [1.16-2.00]) and 'conditional' risk (2.20 [1.42-3.41]). Pairwise comparisons and trend tests based on these classification categories could not demonstrate a significantly increased risk of two or more drugs compared with one drug. CONCLUSION: Beyond suitable single-drug classifications for QT-associated risk estimation, the situation when there is co-prescription of several drugs appears to be complex and may not be extrapolated to all possible multi-drug combinations.
Authors: Hanna M Seidling; Ulrike Klein; Matthias Schaier; David Czock; Dirk Theile; Markus G Pruszydlo; Jens Kaltschmidt; Gerd Mikus; Walter E Haefeli Journal: Int J Med Inform Date: 2014-01-13 Impact factor: 4.046
Authors: Sean Hennessy; Charles E Leonard; Cristin P Freeman; Rajat Deo; Craig Newcomb; Stephen E Kimmel; Brian L Strom; Warren B Bilker Journal: Pharmacoepidemiol Drug Saf Date: 2010-06 Impact factor: 2.890
Authors: Charlotte P M Heemskerk; Marieke Pereboom; Karlijn van Stralen; Florine A Berger; Patricia M L A van den Bemt; Aaf F M Kuijper; Ruud T M van der Hoeven; Aukje K Mantel-Teeuwisse; Matthijs L Becker Journal: Eur J Clin Pharmacol Date: 2017-11-22 Impact factor: 2.953
Authors: Florine A Berger; Nico Monadian; Natasja M S de Groot; Bart Santbergen; Heleen van der Sijs; Matthijs L Becker; Annoek E C Broers; Teun van Gelder; Patricia M L A van den Bemt Journal: Br J Clin Pharmacol Date: 2017-12-06 Impact factor: 4.335
Authors: Florine A Berger; Heleen van der Sijs; Matthijs L Becker; Teun van Gelder; Patricia M L A van den Bemt Journal: BMC Med Inform Decis Mak Date: 2020-07-23 Impact factor: 2.796
Authors: Andreas D Meid; Irene Bighelli; Sarah Mächler; Gerd Mikus; Giuseppe Carrà; Mariasole Castellazzi; Claudio Lucii; Giovanni Martinotti; Michela Nosè; Giovanni Ostuzzi; Corrado Barbui; Walter E Haefeli Journal: Ther Adv Psychopharmacol Date: 2017-08-28
Authors: Mirjam Hempenius; Kim Luijken; Anthonius de Boer; Olaf Klungel; Rolf Groenwold; Helga Gardarsdottir Journal: Pharmacoepidemiol Drug Saf Date: 2020-05-11 Impact factor: 2.890